Lisa La on the Next 5 Years in Multiple Myeloma Research

Video

The clinical researcher spoke about what she hopes will occur in multiple myeloma research over the next 5 years.

In an interview with CancerNetwork®, Lisa La, director of clinical research in the Center for Cancer Care at White Plains Hospital, discussed what she hopes will occur in multiple myeloma research over the next 5 years.

Transcription:

Hopefully we find a cure for myeloma. The director that I worked with at Sinai, I remember interviewing someone with him and the coordinator asked him specifically, “What is your goal in myeloma? You’re doing all these things. You've dedicated the last 20, 30 years of your life to myeloma into your patients. Your patients have your cell phone number, they call you at your house.” And he said, “To find a cure, as simple as that, why else would I dedicate my life to myeloma?”

And that resonated with me, you know, and I think that his passion and along with other oncologists that I've met along the way, who have focused on myeloma really, really have a passion and hoping to find a cure. And that's what I hope, that we are one step closer each year, and hopefully in 5 years we would have some sort of cure. But patients are living a lot longer, again, from 10 years ago when I started to now, but you know, we have to keep pushing the boundaries to see what else we can do.

Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Related Content